Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: MarketLine (a Datamonitor Company)
$175.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Kyowa Hakko Kirin Co Ltd Receives Marketing Approval of Abstral, Sublingual Tablets for Cancer Pain Treatment


Friday, 20 Sep 2013 03:00am EDT 

Kyowa Hakko Kirin Co Ltd announced that Abstral, sublingual tablet 100μg, 200μg and 400μg (nonproprietary name: fentanyl citrate), has been approved for manufacturing and marketing in Japan. 

Company Quote

1333.0
4.0 +0.30%
2:00am EDT